Ming Y Lim: Demonstrating the Value of Upfront Emicizumab at ISTH 2026
Ming Y Lim, Clinical Associate Professor at the University of Utah, shared on LinkedIn:
”What makes ISTH special is the people.
Every meeting is an opportunity to connect with colleagues across disciplines, exchange ideas, learn from one another, and build collaborations that ultimately improve outcomes for patients around the world.
At ISTH 2026 in Paris, I had the privilege of presenting at the SSC Factor VIII, Factor IX, and Rare Coagulation Disorders Subcommittee led by Susan Shapiro, met with the Dengue Infection in Congenital Bleeding Disorders Working Group led by Nongnuch-Nong Sirachainan, and presenting a poster on the cost-effectiveness of upfront emicizumab use in hospitalized patients with acquired hemophilia A.
Judging by the photo, I was clearly having fun engaging with colleagues who stopped by the poster and shared their insights and questions!
Spoiler alert: Adding upfront emicizumab to standard of care was both more effective and less costly, even at current emicizumab pricing.
So grateful for the opportunity to learn from and collaborate with so many outstanding colleagues, and proud to be part of the ISTH community.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios AndreadisÖ‰ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI